Rate My Professor Janice Chew-Harris

Her research focuses on the measurement, detection, and prognostic performance of novel plasma and urinary biomarkers for cardiovascular diseases, chronic kidney disease, acute kidney injury, and cardiorenal syndromes. Key areas include soluble urokinase plasminogen activator receptor (suPAR), cystatin C for glomerular filtration rate estimation, erythroferrone for myocardial infarction diagnosis, and related markers like NT-proBNP signal peptide. She has authored or co-authored 46 publications, garnering over 615 citations. Notable works include 'Prognostic performance of soluble urokinase plasminogen activator receptor for heart failure or mortality in Western and Asian patients with acute breathlessness' (2024, International Journal of Cardiology), 'Influence of Protein Glycosylation on the Measurement of Soluble Urokinase Plasminogen Activator Receptor' (2025, The Journal of Applied Laboratory Medicine), 'Lean mass modulates glomerular filtration rate in males of normal and extreme body composition' (2014), 'The relative effects of fat versus muscle mass on cystatin C and estimates of renal function in healthy young men' (2012), and 'The performance of contemporary cystatin C-based GFR equations in investigating potential renal injury in patients with respiratory disease' (2014). Her contributions advance risk stratification, early detection, and therapy guidance in acute and progressive cardiac and renal conditions, with expertise in clinical biochemistry, protein chemistry, and body composition analysis.